n | % | OR | 95% CI | p | |
---|---|---|---|---|---|
PRN drugs against pain | |||||
Age | |||||
41–64 | 88/95 | 92.6 | 1.006 | 0.464–2.185 | 0.987 |
65–84 | 4799/5086 | 94.4 | 1.335 | 1.159–1.537 | < 0.001 |
85–110 | 10,413/11,219 | 92.8 | Refa | ||
Gender | |||||
Women | 10,342/11,081 | 93.3 | 1.006 | 0.880–1.149 | 0.931 |
Men | 4958/5319 | 93.2 | Refa | ||
PRN drugs against nausea | |||||
Age | |||||
41–64 | 59/94 | 62.8 | 1.108 | 0.726–1.691 | 0.636 |
65–84 | 3131/5037 | 62.2 | 1.069 | 0.997–1.147 | 0.060 |
85–110 | 6814/11,106 | 61.4 | Refa | ||
Gender | |||||
Women | 6832/10,984 | 62.2 | 1.038 | 0.969–1.113 | 0.285 |
Men | 3172/5253 | 60.4 | Refa | ||
PRN drugs against anxiety | |||||
Age | |||||
41–64 | 79/94 | 84.0 | 0.991 | 0.568–1.730 | 0.975 |
65–84 | 4342/5063 | 85.8 | 1.127 | 1.024–1.240 | 0.014 |
85–110 | 9455/11,172 | 84.6 | Refa | ||
Gender | |||||
Women | 9405/11,041 | 85.2 | 1.017 | 0.926–1.116 | 0.728 |
Men | 4471/5288 | 84.5 | Refa | ||
Pain assessed and documented during the last week of life | |||||
Age | |||||
41–64 | 29/93 | 31.2 | 1.025 | 0.658–1.595 | 0.914 |
65–84 | 1550/4916 | 31.5 | 1.039 | 0.965–1.118 | 0.313 |
85–110 | 3399/10,834 | 31.4 | Refa | ||
Gender | |||||
Women | 3428/10,726 | 32.0 | 1.042 | 0.968–1.121 | 0.277 |
Men | 1550/5117 | 30.3 | Refa | ||
Symptoms other than pain assessed during the last week of life | |||||
Age | |||||
41–64 | 22/87 | 25.3 | 1.572 | 0.966–2.560 | 0.069 |
65–84 | 890/4830 | 18.4 | 1.049 | 0.960–1.146 | 0.294 |
85–110 | 1940/10,692 | 18.1 | Refa | ||
Gender | |||||
Women | 1984/10,584 | 18.7 | 1.080 | 0.988–1.181 | 0.091 |
Men | 868/5025 | 17.3 | Refa | ||
Oral health assessed during the last week of life | |||||
Age | |||||
41–64 | 78/93 | 83.9 | 1.712 | 0.983–2.981 | 0.058 |
65–84 | 3696/4730 | 78.1 | 1.162 | 1.069–1.263 | < 0.001 |
85–110 | 7848/10,359 | 75.8 | Refa | ||
Gender | |||||
Women | 7923/10,286 | 77.0 | 1.112 | 1.025–1.206 | 0.010 |
Men | 3699/4896 | 75.6 | Refa | ||
Next of kin informed about transition to end-of-life care | |||||
Age | |||||
41–64 | 72/90 | 80.0 | 1.630 | 0.970–2.739 | 0.065 |
65–84 | 3549/4733 | 75.0 | 1.224 | 1.131–1.325 | < 0.001 |
85–110 | 7308/10,355 | 70.6 | Refa | ||
Gender | |||||
Women | 7331/10,274 | 71.4 | 0.959 | 0.887–1.036 | 0.289 |
Men | 3598/4904 | 73.4 | Refa | ||
Next of kin offered a follow-up talk after death of the patient | |||||
Age | |||||
41–64 | 69/84 | 82.1 | 1.776 | 1.005–3.140 | 0.048 |
65–84 | 3119/4152 | 75.1 | 1.161 | 1.064–1.265 | 0.001 |
85–110 | 6772/9258 | 73.1 | Refa | ||
Gender | |||||
Women | 6828/9217 | 74.1 | 0.983 | 0.903–1.071 | 0.701 |
Men | 3132/4277 | 73.2 | Refa | ||
Documented decision to shift to end-of-life care | |||||
Age | |||||
41–64 | 75/84 | 89.3 | 1.066 | 0.531–2.141 | 0.858 |
65–84 | 4145/4574 | 90.6 | 1.216 | 1.079–1.371 | 0.001 |
85–110 | 8971/10,050 | 89.3 | Refa | ||
Gender | |||||
Women | 8934/9924 | 90.0 | 1.083 | 0.966–1.215 | 0.171 |
Men | 4257/4784 | 89.0 | Refa | ||
Specialised palliative care team consulted | |||||
Age | |||||
41–64 | 3/95 | 3.2 | 2.895 | 0.902–9.293 | 0.074 |
65–84 | 84/5112 | 1.6 | 1.461 | 1.103–1.937 | 0.008 |
85–110 | 127/11,255 | 1.1 | Refa | ||
Gender | |||||
Women | 147/11,120 | 1.3 | 1.181 | 0.877–1.590 | 0.274 |
Men | 67/5342 | 1.3 | Refa | ||
Someone present at the moment of death | |||||
Age | |||||
41–64 | 85/93 | 91.4 | 1.505 | 0.720–3.147 | 0.277 |
65–84 | 4554/5043 | 90.3 | 1.340 | 1.197–1.501 | < 0.001 |
85–110 | 9724/11,035 | 88.1 | Refa | ||
Gender | |||||
Women | 9691/10,915 | 88.8 | 0.904 | 0.811–1.008 | 0.070 |
Men | 4672/5256 | 88.9 | Refa | ||
Pressure ulcers at death | |||||
Age | |||||
41–64 | 13/94 | 13.8 | 0.829 | 0.460–1.496 | 0.534 |
65–84 | 767/5055 | 15.2 | 0.943 | 0.859–1.036 | 0.221 |
85–110 | 1717/11,156 | 15.4 | Refa | ||
Gender | |||||
Women | 1613/11,031 | 14.6 | 0.876 | 0.799–0.960 | 0.005 |
Men | 884/5274 | 16.8 | Refa |